<DOC>
	<DOC>NCT01061372</DOC>
	<brief_summary>The purpose of this study is to assess efficacy and safety of pregabalin in treating moderate to severe Restless Legs Syndrome in comparison to placebo.</brief_summary>
	<brief_title>12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Idiopathic Restless Legs Syndrome with the presence of all four clinical manifestations of RLS: RLS symptoms occur predominantly in the evening RLS history at least 6 months International Restless Legs Study Group Rating Scale (IRLS) greater than or equal to 15 at the beginning and the end of placebo runin Have greater than or equal to 15 nights with RLS symptoms in the month prior to screening Any secondary RLS Current augmentation due to RLS treatment Placebo responders identified during the placebo runin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>RLS</keyword>
</DOC>